By Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann
content material: melanoma drug discovery and improvement : new paradigms for a brand new millennium / E.A. Sausville ... [et al.] --
Evolutionary biosynthesis of anticancer medicines / George R. Pettit --
a few contemporary advancements within the synthesis and structure-activity courting of novel taxanes / John F. Kadow ... [et al.] --
New new release taxoids and hybrids of microtubule-stabilizing anticancer brokers / Iwao Ojima ... [et al.] --
Discodermolide and taxol : a synergistic drug mix in human carcinoma mobilephone traces / Susan Band Horwitz ... [et al.] --
hugely effective semisynthesis of biologically energetic epothilone derivatives / Gregory D. Vite ... [et al.] --
man made and semisynthetic analogs of epothilones : chemistry and organic task / Karl-Heinz Altmann ... [et al.] --
Synthesis and organic task of epothilones / Ulrich Klar ... [et al.] --
Epothilones and sarcodictyins : from combinatorial libraries to designed analogs / Nicolas Winssinger and K.C. Nicolaou --
Synthesis and structure-activity dating reviews of cryptophycins : a singular category of powerful antimitotic antitumor depsipeptides / Chuan Shih ... [et al.] --
Farnesyltransferase inhibitors as strength anticancer brokers / J.B. Gibbs ... [et al.] --
Farnesyltransferase inhibitors : from squalene synthase inhibitors to the medical agent BMS-214662 / John T. Hunt --
Inhibiting farnesyl protein transferase with Sch-66336 : very likely a selective noncytotoxic treatment for human melanoma / A.G. Taveras ... [et al.] --
Pyrrolo[2,3-d]pyrimidine and pyrazolo[3,4-d]pyrimidine derivatives as selective inhibitors of the EGF receptor tryosine kinase / G. Caravatti ... [et al.] --
STI571 : a brand new remedy modality for CML? / Jürg Zimmermann, Pascal Furet, and Elisabeth Buchdunger --
the invention and improvement of second-generation matrix metalloproteinase inhibitors for the remedy of melanoma / Andy Baxter and John Montana --
customers for antiangiogenic treatments established upon VEGF inhibition / Pascal Furet and Paul W. Manley --
Carbohydrate-based tumor antigens as antitumor vaccine brokers / Jennifer R. Allen and Samuel J. Danishefsky --
medicinal drugs to reinforce the healing efficiency of anticancer antibodies : antibody-drug conjugates as tumor-activated prodrugs / Walter A. Blättler and Ravi V.J. Chari.
Read or Download Anticancer Agents. Frontiers in Cancer Chemotherapy PDF
Similar oncology books
Targeting an exceptionally hard and delicate sector of care The loss of life technique examines the stories of death sufferers. in keeping with large fieldwork carried out in an afternoon care provider for sufferers with incurable illnesses and an inpatient hospice the place the sufferers are drawing close loss of life, the ebook considers the main brilliant but painful time for the human physique, the decline in the direction of loss of life.
This quantity offers a organic and pharmacological heritage for nearby melanoma remedy, innovations and methods for nearby treatments, and particular symptoms and effects for various tumor entities. scientific trial recommendations and designated therapy protocols also are provided. This booklet is key interpreting for researchers and clinicians engaged in looking complicated healing recommendations for melanoma sufferers around the globe.
- Biomarkers of Kidney Disease
- Statistical Thinking for Non-Statisticians in Drug Regulation
- Living With Cancer
Extra resources for Anticancer Agents. Frontiers in Cancer Chemotherapy
MDR resistant human colon tumor cell line. Ratio of IC for HCT 116(VM)46 MDR resistant cell line /IC for HCT 116 sensitive cell line. b C d 50 50 Conclusion Exploring both the southern, tubulin binding region as well as the northern region of paclitaxel was important in the discovery of more efficacious, novel taxanes. Both B M S 184476 (15) and B M S 188797 (6) are presently in Phase I and II clinical trials. Clinical results will determine the relevance and predictive ability of our preclinical selection criteria.
84. 85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. ; Iradier, F . ; Plumet, J. Tetrahedron Lett. 1996, 37, 105-106. Gauthier, D . ; Bender, S. L . Tetrahedron Lett. 1996, 37, 13-16. Ceriotti, G . Nature 1967, 213, 595-596. Gonzalez, D . ; Hudlicky, T. Tetrahedron Lett. 1999, 40, 3077-3080. Pettit, G . ; Herald, C . ; Doubek, D . ; Herald, D . ; Clardy, J. J. Am. Chem. Soc. 1982, 104, 6846-6848. Pettit, G . R. The Bryostatins. In Progress in the Chemistry of Organic Natural Products; Tamm, C h . , Eds.
Walker, D . ; Rubin, J . ; Goldberg, R. ; Adjei, Α. ; Ames, M. M. Clin. Cancer Res. 1999, 5, 525-531. 35. Villalona-Calero, Μ . ; Baker, S. D . ; Aylesworth, C . ; Eckhardt, S. ; Velagopudi, R . ; Toppmeyer, D . ; Razvillas, B . ; V o n Hoff, D . D . ; Rowinsky, E . J. Clin. Oncol. 1998, 16, 2770-2779. 36. Pettit, G . ; Rhodes, M. ; Herald, D . ; Chaplin, D . J . ; Pettit, R. ; Oliva, D . Anti-Cancer Drug Des. 1998, 13, 981-994. ; ACS Symposium Series; American Chemical Society: Washington, DC, 2001.
Anticancer Agents. Frontiers in Cancer Chemotherapy by Iwao Ojima, Gregory D. Vite, Karl-Heinz Altmann